In this issue:
- CX audience deems paclitaxel not dangerous, while vascular pathologist says establishing the truth takes time (p.1)
- EVAR funding threatened, while a strategy for safe, cost-effective repair is “just around the corner” (p.1)
- Marianne Broadmann outlines follow-up and surveillance protocols after endovascular treatments for peripheral arterial disease (p.22)
- Profile: Kim Hodgson (p.26)
